INVIVO PERSISTENCE OF EXPANDED CLONES SPECIFIC FOR BACTERIAL-ANTIGENSWITHIN THE HUMAN T-CELL RECEPTOR-ALPHA-BETA CD4-8- SUBSET

Citation
P. Dellabona et al., INVIVO PERSISTENCE OF EXPANDED CLONES SPECIFIC FOR BACTERIAL-ANTIGENSWITHIN THE HUMAN T-CELL RECEPTOR-ALPHA-BETA CD4-8- SUBSET, The Journal of experimental medicine, 177(6), 1993, pp. 1763-1771
Citations number
51
Categorie Soggetti
Immunology,"Medicine, Research & Experimental
ISSN journal
00221007
Volume
177
Issue
6
Year of publication
1993
Pages
1763 - 1771
Database
ISI
SICI code
0022-1007(1993)177:6<1763:IPOECS>2.0.ZU;2-W
Abstract
We analyzed the T cell receptor (TCR) rearrangements of 100 TCR-alpha/ beta CD4-CD8- (double negative [DN]) T cell clones from normal individ uals. We found that in four out of six donors this subset contains exp anded clones that often account for 0.5% and, in one individual, even 7% of all peripheral blood lymphocytes. By combining limiting dilution analysis and N region oligotyping of polymerase chain reaction amplif ied TCR cDNA, we could measure the clonal size and show that two of th ese expanded clones remain stable in size for up to 4 yr in peripheral blood. The expanded clones analyzed ex vivo are not cycling and CD45 RA(hi) RO(lo), but express high levels of alpha4/beta1 integrins, sugg esting that they may have reverted to resting cells after activation. One of these expanded DN clones proliferates in vitro in response to E scherichia coli presented by monocytes cultured in GM-CSF plus IL-4 an d kills CD1a+ Molt-4 cells. In contrast to what was found in the alpha /beta DN subset, alpha/beta CD4+ T cell clones specific for a tetanus toxin epitope showed a very small clonal size (<1 in 10(7)) and could not be reisolated after 2 yr. Taken together, these results indicate t hat large clonal size and persistence are distinctive features of alph a/beta DN cells specific for bacterial antigens. These cells may use a ntigen-presenting cells, restriction molecules, and selection routes d ifferent from those used by antigen-specific CD4+ T cells.